Prosecution Insights
Last updated: August 18, 2026

Examiner: JONES-FOSTER, ERICA NICOLE

Tech Center 1600 • Art Units: 1612 1632 1644 1656

This examiner grants 50% of resolved cases

Performance Statistics

50.0%
Allow Rate
-10.0% vs TC avg
150
Total Applications
+47.5%
Interview Lift
1237
Avg Prosecution Days
Based on 76 resolved cases, 2023–2026

Rejection Statute Breakdown

8.2%
§101 Eligibility
20.4%
§102 Novelty
38.7%
§103 Obviousness
23.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17795939 COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF Non-Final OA Flagship Pioneering Innovations VI, LLC
17185196 GENETICALLY MODIFIED BACTERIAL CELLS AND METHODS USEFUL FOR PRODUCING TETRAMETHYL PYRAZINE Final Rejection The Regents of the University of California
17437232 MICROBIAL TEST KIT, MICROBIAL TEST METHOD AND MICROBIAL TEST DEVICE Non-Final OA HITACHI HIGH-TECH CORPORATION
18701910 METHOD FOR PRODUCING REBAUDIOSIDE D AND REBAUDIOSIDE M Non-Final OA CJ CHEILJEDANG CORPORATION
18682348 POLYNUCLEOTIDE ENCODING A BACTERIAL COLLAGEN-LIKE PROTEIN Non-Final OA Evonik Operations GmbH
18570018 NONANIC ACID ESTERS Final Rejection Evonik Operations GmbH
17784693 Methods and compositions for modulating the glycosylation profile of proteins Non-Final OA Merck Patent GmbH
17430969 MYC, CYCLIN T1 AND/OR CDK9 FOR USE IN THE TREATMENT OF DEGENERATIVE HEART AND CNS DISORDERS Final Rejection CAMBRIDGE ENTERPRISE LIMITED
17258132 NOVEL MICROORGANISMS FOR DECOMPOSING OIL AND FAT CONTAINING FATTY ACID Non-Final OA National University Corporation Tokai National Higher Education and Research System
17366443 COMPOSITIONS, KITS AND METHODS USEFUL FOR SEPARATING PROTEINS FROM SURFACTANTS Final Rejection Waters Technologies Corporation
18036580 USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE Final Rejection HANMI PHARM. CO., LTD.
18036538 USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF NEUROPATHY CAUSED BY OR ACCOMPANIED BY FABRY DISEASE Final Rejection HANMI PHARM. CO., LTD.
17945293 PROBIOTICS FOR USE IN REDUCING THE INCIDENCE AND DURATION OF ILLNESS Final Rejection DUPONT NUTRITION BIOSCIENCES APS
17786111 METHODS AND SYSTEMS FOR PATHOGEN MITIGATION IN ORGANIC MATERIALS Final Rejection Plant Response, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month